These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 25742086)
1. Intensive care unit admission rates for respiratory syncytial virus infection as a function of age in preterm infants born at 32-35-week gestation and not receiving immunoprophylaxis. Simões EA; Ambrose CS; Wu X; Anderson EJ Pediatr Infect Dis J; 2015 Mar; 34(3):331. PubMed ID: 25742086 [No Abstract] [Full Text] [Related]
2. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age. Park HW; Lee BS; Kim AR; Yoon HS; Kim BI; Song ES; Kim WT; Lim J; Kim S; Jin HS; Byun S; Chee DH; Kim KS Pediatr Infect Dis J; 2012 Aug; 31(8):e99-104. PubMed ID: 22531234 [TBL] [Abstract][Full Text] [Related]
3. [Guidelines for respiratory syncytial virus prophylaxis. An update]. Carbonell-Estrany X; Quero Jiménez J An Esp Pediatr; 2002 Apr; 56(4):334-6. PubMed ID: 11927077 [TBL] [Abstract][Full Text] [Related]
4. Rehospitalization for respiratory syncytial virus among premature infants. Joffe S; Escobar GJ; Black SB; Armstrong MA; Lieu TA Pediatrics; 1999 Oct; 104(4 Pt 1):894-9. PubMed ID: 10506231 [TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251 [TBL] [Abstract][Full Text] [Related]
6. Prevention of respiratory syncytial viral infections in late preterm infants. Sankaran K; Kalappurackal M; Tan B Zhongguo Dang Dai Er Ke Za Zhi; 2013 Apr; 15(4):241-8. PubMed ID: 23607943 [TBL] [Abstract][Full Text] [Related]
7. Late preterm infants and risk for RSV. Coffman S MCN Am J Matern Child Nurs; 2009; 34(6):378-84; quiz 385-6. PubMed ID: 19901700 [TBL] [Abstract][Full Text] [Related]
8. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580 [TBL] [Abstract][Full Text] [Related]
9. Respiratory syncytial virus (RSV) outbreak in the NICU: description of eight cases. Kilani RA J Trop Pediatr; 2002 Apr; 48(2):118-22. PubMed ID: 12022427 [TBL] [Abstract][Full Text] [Related]
10. Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions. Weisman L Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S33-7; discussion S37-9. PubMed ID: 12671450 [TBL] [Abstract][Full Text] [Related]
11. Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age. Stensballe LG; Fullarton JR; Carbonell-Estrany X; Simões EA Pediatr Infect Dis J; 2010 Apr; 29(4):374-6. PubMed ID: 20016397 [TBL] [Abstract][Full Text] [Related]
12. Nosocomial respiratory syncytial virus: a threat in the modern neonatal intensive care unit. Heerens AT; Marshall DD; Bose CL J Perinatol; 2002 Jun; 22(4):306-7. PubMed ID: 12032794 [No Abstract] [Full Text] [Related]
14. Pseudo-outbreak of respiratory syncytial virus infection in a neonatal intensive care unit due to cross-reactivity of surfactant and a rapid immunoassay. Terashita Gastelum D; Peterson A; Mascola L; Dassey D; Camargo E Infect Control Hosp Epidemiol; 2009 Sep; 30(9):890-2. PubMed ID: 19619057 [TBL] [Abstract][Full Text] [Related]
15. Increased risk for respiratory syncytial virus-associated, community-acquired alveolar pneumonia in infants born at 31-36 weeks of gestation. Greenberg D; Dagan R; Shany E; Bar-Ziv J; Givon-Lavi N Pediatr Infect Dis J; 2014 Apr; 33(4):381-6. PubMed ID: 24145171 [TBL] [Abstract][Full Text] [Related]
16. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Figueras-Aloy J; Carbonell-Estrany X; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E; Pediatr Infect Dis J; 2008 Sep; 27(9):788-93. PubMed ID: 18664927 [TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Liese JG; Grill E; Fischer B; Roeckl-Wiedmann I; Carr D; Belohradsky BH; Eur J Pediatr; 2003 Apr; 162(4):230-6. PubMed ID: 12647195 [TBL] [Abstract][Full Text] [Related]
18. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173 [TBL] [Abstract][Full Text] [Related]
19. Palivizumab use in very premature infants in the neonatal intensive care unit. Wu SY; Bonaparte J; Pyati S Pediatrics; 2004 Nov; 114(5):e554-6. PubMed ID: 15520088 [TBL] [Abstract][Full Text] [Related]
20. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey. Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]